Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome

In this week's episode we’ll discuss the mutational and transcriptional landscape of pediatric BCP lymphoblastic leukemia; learn more about the role of platelet-derived TGF-β1 in immune thrombocytopenia; and discuss the findings from a phase 3 trial of mavorixafor in WHIM syndrome.

Featured Articles:

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma
Platelet-derived TGF-β1 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia
Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome

Om avsnittet

Fler avsnitt

Designing Durable Remissions in Relapsed AML and Follicular Lymphoma

Dose Makes the Cure: Venetoclax in Ph- ALL

Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome

MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow

Predictive Markers of Glofitamab Resistance in R/R B-NHL

Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM

Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

FLT3-ITD microclones in AML and Results from the RESET-PV trial